Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.

ABSTRACT:

Background

The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12 years of age with uncontrolled, moderate-to-severe asthma. Overall, safety was consistent with the known dupilumab safety profile. This post hoc analysis assessed long-term dupilumab efficacy for up to 3 years by exacerbation history.

Patients and methods

Unadjusted annualised severe exacerbation rates (AER) and change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV₁) and 5-item Asthma Control Questionnaire (ACQ-5) score were assessed in patients with PSBL

SUBMITTER: Corren J 

PROVIDER: S-EPMC10584079 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature